Active Ingredient History
Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has few to no central effects. It is given by mouth, via intravenous injection, on the skin, and via inhalation. It is a synthetic quaternary ammonium compound. The cation, which is the active moiety, is called glycopyrronium (INN) or glycopyrrolate (USAN). Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Abdominal Neoplasms (Phase 4)
Anesthesia (Phase 4)
Anesthesia and Analgesia (Phase 4)
Bronchoscopy (Phase 4)
Burns (Phase 3)
Constipation (Phase 1)
Coronary Artery Disease (Phase 4)
Delayed Emergence from Anesthesia (Phase 4)
Epilepsy (Phase 4)
Fecal Incontinence (Early Phase 1)
Fractures, Bone (Phase 4)
General Surgery (Phase 4)
Headache (Phase 4)
Hydrocephalus (Phase 4)
Laryngoscopy (Phase 4)
Neoplasm Metastasis (Phase 4)
Neoplasms (Phase 4)
Neurodevelopmental Disorders (Phase 4)
Neurofibromatoses (Phase 4)
Neurogenic Bowel (Phase 1)
Neuromuscular Blockade (Phase 4)
Pharmacokinetics (Phase 1)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Sialorrhea (Phase 4)
Spinal Cord Injuries (Phase 1)
Spinal Injuries (Phase 4)
Urinary Bladder Neoplasms (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue